Form 8-K · Current Report · Filed 2025-04-25
Revvity, Inc. Announces Adoption of Majority Voting Standard and Election of New Directors
Revvity, Inc. announced the adoption of a majority voting standard for corporate actions and the election of new directors at its annual shareholder meeting held on April 22, 2025. Shareholders approved amendments to the company's Restated Articles of Organization and Amended and Restated By-laws to implement the majority voting standard. All ten nominees for director were elected, and other proposals including the ratification of Deloitte & Touche LLP as the independent public accounting firm and the approval of executive compensation by non-binding advisory vote were also approved. The amended by-laws are effective as of April 24, 2025.
- Filer
- Revvity Inc. RVTY · NYSE
- Filed
- Accession
- 0001193125-25-096747
- CIK
- 0000031791
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Amendments to Articles of Incorporation or Bylaws
Submission of Matters to a Vote of Security Holders
Financial Statements and Exhibits
Market reaction
Close before filing
$95.13
Next session
-0.1%
Since filing
+54.2%
Latest close
$146.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVTY reporting the same item, with the next session's move:
Exhibits (3)
About Revvity Inc.
Revvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, and services for research, development, and clinical testing. Revvity’s current business is organized around two main segments: Life Sciences, which supplies reagents, instruments, and software to support biopharma and academic research; and Diagnostics, which offers assay platforms, instruments, and software for reproductive health, immunodiagnostics, newborn screening, applied genomics, and infectious disease testing. The company also focuses on translational multi-omics, biomarker identification, imaging, screening, detection, and informatics, helping customers move biological data through connected laboratory workflows. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations across global markets. Headquartered in Waltham, Massachusetts, Revvity plays an important role in enabling scientific discovery and supporting clinical decision-making across the healthcare and research ecosystem.
Never miss another RVTY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.